SCHEMBL13310239

SCHEMBL13310239

COc1ccc(/C=N/Nc2nc3nonc3nc2Nc2ccccc2OC)cc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.47
GAA P10253 8/20 0.47
MEN1 O00255 6/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 8/20 0.47
KDM4E B2RXH2 3/20 0.47
POLB P06746 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
USP2 O75604 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 6/20 0.44
RAB9A P51151 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
GFER P55789 3/20 0.44
MPO P05164 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506779 0.85 MPO (0.49) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6506776 0.85 MPO (0.49) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL13310246 0.79 KMT2A (0.49) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6721450 0.78 MAPT (0.52) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL20569973 0.78 ALDH1A1 (0.69) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6505459 0.76 GAA (0.57) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6505451 0.76 GAA (0.57) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL8266101 0.76 KMT2A (0.44) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6436752 0.76 KMT2A (0.44) KMT2AGAAMEN1ALDH1A1MAPT
SCHEMBL6419647 0.72 GAA (0.52) KMT2AGAAMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE ABCG2, NQO2, TOP1 KMT2A 1733/4885GAA 1259/4885MEN1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.